Holen Sie sich die Stockscreener-App
4.5438
0.48%
0.0338
Schlusskurs vom Vortag:
$4.51
Offen:
$4.44
24-Stunden-Volumen:
47,803
Relative Volume:
0.19
Marktkapitalisierung:
$42.49M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.99%
1M Leistung:
-88.74%
6M Leistung:
-83.05%
1J Leistung:
+0.00%
1-Tages-Spanne:
$4.40
$4.5699
1-Wochen-Bereich:
$4.40
$5.00
52-Wochen-Spanne:
$4.40
$43.65
Tvardi Therapeutics Inc Stock (TVRD) Company Profile
Firmenname
Tvardi Therapeutics Inc
Sektor
Branche
Telefon
(713) 489-8654
Adresse
3 SUGAR CREEK CTR. BLVD., SUGAR LAND
Vergleichen Sie TVRD mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TVRD
Tvardi Therapeutics Inc
|
4.5315 | 42.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.77 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
636.50 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
427.86 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
843.08 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
185.58 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Tvardi Therapeutics Inc Stock (TVRD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2025-10-14 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2025-10-13 | Eingeleitet | Barclays | Overweight |
| 2025-10-13 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2025-10-13 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2025-07-14 | Eingeleitet | Raymond James | Outperform |
| 2025-07-11 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-06-12 | Eingeleitet | Piper Sandler | Overweight |
| 2025-05-21 | Eingeleitet | Oppenheimer | Outperform |
| 2025-05-15 | Eingeleitet | BTIG Research | Buy |
| 2024-06-13 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2024-06-13 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2024-06-13 | Herabstufung | Needham | Buy → Hold |
| 2024-06-13 | Herabstufung | Stifel | Buy → Hold |
| 2023-03-08 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-03-08 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-11-01 | Fortgesetzt | Canaccord Genuity | Buy |
| 2021-08-03 | Eingeleitet | JP Morgan | Neutral |
| 2020-04-21 | Bestätigt | H.C. Wainwright | Buy |
| 2019-08-12 | Bestätigt | H.C. Wainwright | Buy |
| 2019-05-29 | Bestätigt | Laidlaw | Buy |
| 2019-02-06 | Fortgesetzt | Jefferies | Buy |
| 2019-01-15 | Eingeleitet | BofA/Merrill | Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-13 | Eingeleitet | Jefferies | Buy |
| 2018-08-08 | Bestätigt | Stifel | Buy |
| 2018-06-28 | Bestätigt | H.C. Wainwright | Buy |
| 2018-03-12 | Fortgesetzt | H.C. Wainwright | Buy |
| 2018-02-12 | Hochstufung | Janney | Neutral → Buy |
| 2018-01-19 | Eingeleitet | Seaport Global Securities | Buy |
Alle ansehen
Tvardi Therapeutics Inc Aktie (TVRD) Neueste Nachrichten
Tvardi Therapeutics to Participate in the Jefferies Global Healthcare Conference in London - MarketScreener
Is Tvardi Therapeutics Inc. stock ready for a breakoutWeekly Trend Summary & AI Based Trade Execution Alerts - newser.com
Is Tvardi Therapeutics Inc. (69C) stock a safe buy pre earnings2025 Technical Patterns & High Yield Stock Recommendations - newser.com
How to track smart money flows in Tvardi Therapeutics Inc.July 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Technical signs of recovery in Tvardi Therapeutics Inc.2025 Major Catalysts & Technical Entry and Exit Tips - newser.com
Tvardi Therapeutics (TVRD) Competitors and Alternatives 2025 - MarketBeat
Shareholders Alert: Investigation Into Tvardi Therapeutics, Inc. (TVRD)Contact Levi & Korsinsky to Protect Your Rights - ACCESS Newswire
Tvardi Therapeutics, Inc. (TVRD) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Tvardi Therapeutics - The Malaysian Reserve
Why Tvardi Therapeutics Inc. (69C) stock could outperform next yearWeekly Volume Report & High Yield Equity Trading Tips - newser.com
Measuring Tvardi Therapeutics Inc.’s beta against major indicesWeekly Investment Report & Weekly Watchlist of Top Performers - newser.com
Understanding Tvardi Therapeutics Inc.’s price movementIPO Watch & Reliable Entry Point Alerts - newser.com
Does Tvardi Therapeutics Inc. stock trade at a discount to peersChart Signals & Reliable Price Action Trade Plans - newser.com
Can Tvardi Therapeutics Inc. (69C) stock hold up in economic slowdownMarket Performance Report & Daily Price Action Insights - newser.com
Will Tvardi Therapeutics Inc. stock benefit from green energy trendsWeekly Investment Recap & Weekly Return Optimization Plans - newser.com
What data driven models say about Tvardi Therapeutics Inc.’s futureJuly 2025 Final Week & Technical Pattern Recognition Alerts - newser.com
Heatmap analysis for Tvardi Therapeutics Inc. and competitors2025 Big Picture & Real-Time Volume Surge Alerts - newser.com
How to interpret RSI for Tvardi Therapeutics Inc. stockTake Profit & Weekly Breakout Stock Alerts - newser.com
Can Tvardi Therapeutics Inc. stock deliver consistent earnings growthJuly 2025 Movers & AI Based Buy and Sell Signals - newser.com
Using Bollinger Bands to evaluate Tvardi Therapeutics Inc.July 2025 Intraday Action & Free Fast Gain Swing Trade Alerts - newser.com
Key resistance and support levels for Tvardi Therapeutics Inc.Portfolio Growth Summary & High Accuracy Buy Signal Tips - newser.com
What to do if you’re stuck in Tvardi Therapeutics Inc.July 2025 Pullbacks & Safe Capital Growth Stock Tips - newser.com
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
2025-11-02 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Investors to Learn More About the Investigation | NDAQ:TVRD | Press Release - Stockhouse
Tvardi Therapeutics, Inc. (TVRD) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Why Tvardi Therapeutics Inc. stock is recommended by analystsJuly 2025 Highlights & Free Low Drawdown Momentum Trade Ideas - newser.com
How Tvardi Therapeutics Inc. stock reacts to global recession fears2025 Support & Resistance & Verified Swing Trading Watchlists - newser.com
Will Tvardi Therapeutics Inc. benefit from macro trendsJuly 2025 Review & Capital Protection Trading Alerts - newser.com
TVRD Investors Have Opportunity to Join Tvardi Therapeutics, Inc. Fraud Investigation with the Schall Law Firm - The AI Journal
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Stockholders to Learn More About the Investigation - ACCESS Newswire
2025-10-31 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Tvardi Therapeutics, Inc. (TVRD) and Encourages Stockholders to Learn More About the Investigation | NDAQ:TVRD | Press Release - Stockhouse
Using AI based signals to follow Tvardi Therapeutics Inc.2025 Market Sentiment & Breakout Confirmation Trade Signals - newser.com
Finanzdaten der Tvardi Therapeutics Inc-Aktie (TVRD)
Es liegen keine Finanzdaten für Tvardi Therapeutics Inc (TVRD) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
1.85%
0.26%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):